DepYmed to Present Early Data on Its Small Molecule PTP1B Inhibitor Program at the 2023 IRSF Rett Syndrome Scientific Meeting FARMINGDALE, New York, May 31, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for...